ArticlePLoS neglected tropical diseases2015
African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07045493 (Assessing Safety and Efficacy of Ivermectin and Albendazole Combination Therapy for Soil-transmitted Helminthiasis in Pre-school-aged Children), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Safety and Efficacy of Ivermectin and Albendazole Combination Therapy for Soil-transmitted Helminthiasis in Pre-school-aged Children (PSAC) in Bangladesh
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Economic evaluations of onchocerciasis interventions: a systematic review and research needs.Tropical medicine & international health : TM & IH · 2019Pooled it
- Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis.PLoS neglected tropical diseases · 2018Pooled it
- Integrated strategies for controlling and eliminating Neglected Tropical Diseases in Sub-Saharan Africa: a review of approaches, challenges, and opportunities.Tropical diseases, travel medicine and vaccines · 2026Review
- Community engagement in mass drug administration participatory interventions: A scoping review.PLoS neglected tropical diseases · 2025Article
- Scabies.Nature reviews. Disease primers · 2024Review
- Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial.Malaria journal · 2024Article
- Status of Onchocerciasis Elimination in Gabon and Challenges: A Systematic Review.Microorganisms · 2023Review
- Article
- Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?BMJ global health · 2021Review
- The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.PLoS neglected tropical diseases · 2021Article
- Community-directed distributors-The "foot soldiers" in the fight to control and eliminate neglected tropical diseases.PLoS neglected tropical diseases · 2021Review
- Impact of Community Treatment With Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- The prevalence of scabies, pyoderma and other communicable dermatoses in the Bijagos Archipelago, Guinea-Bissau.PLoS neglected tropical diseases · 2019Article
- Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions.Infectious diseases of poverty · 2019Article
- Prevalence, Intensity of Soil-Transmitted Helminths, and Factors Associated with Infection: Importance in Control Program with Ivermectin and Albendazole in Eastern Côte d'Ivoire.Journal of tropical medicine · 2019Article
- Integrated Management of Skin NTDs-Lessons Learned from Existing Practice and Field Research.Tropical medicine and infectious disease · 2018Review
- The Skin-A Common Pathway for Integrating Diagnosis and Management of NTDs.Tropical medicine and infectious disease · 2018Review
- Onchodermatitis: Where Are We Now?Tropical medicine and infectious disease · 2018Review
- Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations.The Journal of antibiotics · 2017Review
- Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis.Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its initiation in 1995, the African Program for Onchocerciasis Control (APOC) has had a substantial impact on the prevalence and burden of onchocerciasis through annual ivermectin mass treatment. Ivermectin is a broad-spectrum anti-parasitic agent that also has an impact on other co-endemic parasitic infections. In this study, we roughly assessed the additional impact of APOC activities on the burden of the most important off-target infections: soil-transmitted helminthiases (STH; ascariasis, trichuriasis, hookworm, and strongyloidiasis), lymphatic filariasis (LF), and scabies. Based on a literature review, we formulated assumptions about the impact of ivermectin treatment on the disease burden of these off-target infections. Using data on the number of ivermectin treatments in APOC regions and the latest estimates of the burden of disease, we then calculated the impact of APOC activities on off-target infections in terms of disability-adjusted life years (DALYs) averted. We conservatively estimated that between 1995 and 2010, annual ivermectin mass treatment has cumulatively averted about 500 thousand DALYs from co-endemic STH infections, LF, and scabies. This impact comprised approximately an additional 5.5% relative to the total burden averted from onchocerciasis (8.9 million DALYs) and indicates that the overall cost-effectiveness of APOC is even higher than previously reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.